Third-Party Tested by Verum Analytics
GLP1-S
Long-acting GLP-1 receptor agonist — the most-studied peptide for weight loss and metabolic health.
Third-Party Tested by Verum Analytics
Albert's Verdict
GLP1-S operates on the same receptor as the most clinically validated metabolic drugs in history, but in a research peptide format. The beta-cell preservation and gastric motility data make this one of the most referenced compounds in our metabolic category.
View COAArrives as lyophilized (powder) form
Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.
Product Description
GLP1-S is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has become the most-studied metabolic peptide of the decade. It slows gastric emptying, enhances insulin sensitivity, and dramatically reduces appetite — making it the reference standard for weight-loss and Type 2 diabetes research.
The STEP UP trial (2025) demonstrated that higher doses achieved ~21% mean weight loss vs 15.6% at lower doses, with over 90% of participants achieving at least 5% loss and one-third losing ≥25% of body weight. Convenient once-weekly dosing with a substantial cardiovascular-benefit and MASH dataset behind it. For research use only. Not for human or veterinary consumption.
Technical Specifications
- Molecular Formula
- C187H291N45O59
- Molecular Weight
- 4113.58 g/mol
- Sequence
- His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Customer Reviews
Verified research purchases
Legit quality - verified myself
The purity checked out when I verified the COA on the lab's website. Shipped with ice packs and arrived in perfect condition. This is how every supplier should operate.
Fast shipping, great packaging
Ordered on Monday, arrived Wednesday. Package was cold and properly sealed. The quality is exactly what I expected based on the reviews. Happy customer.
Switched from another supplier
My previous supplier was inconsistent. BioInfinity's COAs are verifiable and the quality is consistent batch after batch. Worth the switch.
Bulk discount saved me money
The 15% off for 3+ units made this more affordable than other options. Quality is top notch and shipping was faster than expected.
Fifth order and counting
Been a customer for over a year now. The quality and service have been consistently excellent every single time. My go-to source.
Customer service actually helps
Had questions about storage and they responded same day with helpful info. Nice to deal with a company that actually cares about their customers.
You get what you pay for
Tried cheaper options before but the quality was sketchy. BioInfinity's third-party testing gives me confidence. Worth the price.
COA matches reality
The product matches the COA specs. That sounds basic but you'd be surprised how many suppliers don't deliver on their claims. These guys do.
Frequently Researched Together
Commonly studied alongside in laboratory settings
Research FAQ — GLP1-S
Frequently asked questions about this compound for laboratory researchers.
What is Semaglutide / GLP-1-S?+
What does STEP-1 research data show?+
How is Semaglutide dosed in published research?+
How is Semaglutide stored?+
Published research references
Peer-reviewed literature relevant to GLP1-S research. Linked PubMed IDs open the original source.
- [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — N Engl J Med (2021) · PMID 33567185
- [2]Semaglutide and cardiovascular outcomes in obesity without diabetes — N Engl J Med (2023) · PMID 34882832
- [3]Effect of Subcutaneous Semaglutide vs Placebo on Cardiovascular Outcomes (SUSTAIN-6) — N Engl J Med (2016) · PMID 31185157
Learn More About This Peptide
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.
GLP1-S — clinical & mechanistic profile
GLP1-S (Semaglutide) is an FDA-approved GLP-1 receptor agonist with 94% homology to human GLP-1. A 2026 meta-analysis confirms 17.1% mean weight loss at 12 months, with tirzepatide showing superior results (-22.1%). Cardiovascular outcomes trials demonstrate significant reduction in MACE events. Ongoing research explores oral formulations and combination therapies.
Research status
clinical investigational
Molecular weight
4113.58 Da
Molecular formula
C187H291N45O59
Studied applications
- •GLP-1 receptor agonism: the primary mechanism triggering insulin secretion and metabolic effects
- •Weight management: extensive clinical trial data showing significant weight reduction
- •Glycemic control: proven efficacy in type 2 diabetes for HbA1c reduction
- •Cardiovascular protection: demonstrated reduction in major adverse cardiovascular events
- •Long-acting design: once-weekly injectable formulation due to DPP-4 resistance and albumin binding
Mechanisms of action
- •GLP-1 receptor binding: selectively activates GLP-1R, a G protein-coupled receptor on pancreatic beta cells
- •cAMP/PKA pathway: triggers adenylate cyclase activation, increasing cyclic AMP and protein kinase A activity
- •Insulin secretion: enhances glucose-dependent insulin exocytosis from beta cells
- •Glucagon suppression: inhibits glucagon release from alpha cells, reducing hepatic glucose production
- •Gastric emptying delay: slows stomach emptying, contributing to satiety and glycemic control
- •Appetite regulation: activates hypothalamic GLP-1R, suppressing hunger and reducing food intake
- •FDA-APPROVED DRUG: Prescription pharmaceutical products (GLP1-S, GLP1-S, GLP1-S) require medical supervision
- •Research use is separate from clinical use—research compounds are not for human consumption
- •Gastrointestinal side effects are common (nausea, vomiting, especially during dose escalation)
- •Contraindications include personal/family history of medullary thyroid carcinoma or MEN2
- •Not for use in type 1 diabetes or diabetic ketoacidosis
Peer-reviewed references
- Marso SP, et al. — SUSTAIN-6 cardiovascular outcomes trialPMID: 28930514View
- Wilding JPH, et al. — STEP 1 weight management trialPMID: 34170647View
- SELECT trial cardiovascular outcomes (2023)PMID: 36324598View
- GLP1-S mechanism of action reviewPMID: 33567185View
- GLP-1 agonists neuroprotective potentialPMID: 35658024View
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.